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Abstract Meropenem is a carbapenem antibiotic that
exhibits time-dependent bactericidal activity, traditionally
dosed intravenously at 1 g every 8 h. In order to maximize
its pharmacodynamic activity and reduce costs, an alter-
native regimen employed by many institutions is 500 mg
every 6 h. The objective of this review was to summarize
and evaluate published literature comparing clinical out-
comes associated with these two meropenem dosing regi-
mens. The literature was searched up to October 2016
using the MEDLINE, EMBASE, and Google Scholar
databases. Three retrospective cohort studies were identi-
fied that compared clinical outcomes in general infectious
disease patients (two studies) and patients with febrile
neutropenia (one study). All studies reported no difference
in clinical outcomes (clinical success, time to deferves-
cence, sign or symptom resolution, length of stay, mor-
tality, need for other antibiotics, and seizure rates). One
study reported reduced economic costs with the alternative
dosing. Interpretation of findings was primarily limited by
small sample sizes and generalizability. Based on the data
reviewed, the alternative dosing regimen of meropenem
500 mg intravenously every 6 h could be considered a
therapeutic option. Future studies are needed to confirm the
findings of this review, especially in high-risk populations
such as immunocompromised patients or those with severe
infections.
Key Points
Meropenem dosing of 500 mg every 6 h did not
differ in clinical outcomes with a dosing strategy of
1 g every 8 h.
The alternative dosing strategy may result in
institutional cost savings due to lower drug
acquisition costs.
1 Introduction
Appropriate use of antibiotics is a major target for health
systems worldwide [1]. It is well known that antimicrobial
overuse can contribute to poor patient outcomes, through
promotion of antibiotic resistance, increased adverse
events, and prolonged length of hospital stay [2]. These
considerations can be detrimental to patients, as fewer
agents are being developed to combat resistant infections
[3]. Additionally, antibiotic-associated resistance is a major
expenditure for institutions and is resulting in a heavy
global economic burden [4]. The clinical, epidemiological,
and economic burdens of antibiotic overuse must be
addressed to preserve the effectiveness of drug therapy and
sustainability of health systems. Aside from antimicrobial
stewardship, other strategies can be employed to improve
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the use of antibiotics and minimize associated costs.
Optimization of dosing strategies, route of administration,
and duration of therapy are considerations that can
decrease overuse and wastage of targeted agents [5].
Meropenem, a carbapenem antibiotic that exhibits
broad-spectrum activity, is an agent that has sparked clin-
ical controversy regarding the most appropriate dosing
strategy [6]. Traditionally, intravenous meropenem is
dosed at 1000 mg given every 8 h. Alternative regimens
have been studied in pre-clinical and pharmacokinetic
studies, in order to determine equivalence through phar-
macokinetic and pharmacodynamic perspectives [7]. For
meropenem, its bactericidal activity is unrelated to plasma
concentrations, but is instead dependent on the percentage
of time the plasma concentrations are maintained above the
minimum inhibitory concentration of the pathogen
(%T[MIC) [8]. Therefore, theoretically, lower doses
given at more frequent intervals would optimize its killing
activity. More specifically, a dose of 500 mg given every
6 h is purported to demonstrate the same %T[MIC to the
traditional dosing regimen of 1000 mg every 8 h, and
therefore is speculated to provide similar clinical effects.
Although studies have assessed this alternative dosing
strategy through a pharmacokinetic–pharmacodynamic
perspective, clinical outcomes and comparison data
between these different dosing regimens are lacking
[9–11]. However, studies do suggest that this alternative
dosing strategy will likely result in adequate pharmaco-
dynamic endpoints to treat most non-severe infections.
Even though previous reviews have attempted to pro-
vide a better understanding of meropenem dosing strategies
[6, 8], no review has been published that comprehensively
compares the two dosing regimens mentioned above from
an evidence-based clinical perspective. Therefore, the
objective of this review is to evaluate and summarize the
published literature comparing the clinical outcomes
between administration of intravenous meropenem dosed
at 1000 mg every 8 h and 500 mg every 6 h.
2 Methods
A search of MEDLINE (1948–October 2016), EMBASE
(1980–October 2016), and Google Scholar was conducted
using combinations of the following search terms: ‘‘mer-
openem’’ or ‘‘carbapenem’’ with ‘‘dosage,’’ ‘‘pharmaco-
dynamics,’’ and ‘‘clinical outcomes.’’ The search was
limited to English-language studies in human subjects.
Articles were included in the review if they compared
traditional (1000 mg every 8 h) dosing with alternative
(500 mg every 6 h) dosing. Appropriately adjusted dosing
for each regimen was allowed for compromised renal
function if patients were analyzed as a whole. Articles were
excluded if they were solely in patients with compromised
renal function or in those receiving renal replacement
therapy, or if no clinical outcomes were described. Clinical
outcomes were defined as any outcome measure relating to
efficacy or safety of drug therapy, including clinical suc-
cess, mortality, length of hospital stay, duration of therapy,
time to resolution of symptoms, or adverse events. Two
investigators independently completed the literature search
and assessed articles for inclusion. Discrepancies were
resolved through discussion and consensus. Data were
extracted as reported from the studies, and no further sta-
tistical analyses were performed. The quality of articles
was assessed using the Critical Appraisal Skills Programme
(CASP) Cohort Study Checklist [12].
3 Results
A total of 1107 articles were identified. Thirty-two articles
remained after title and abstract screening. After full-text
review, three articles met the inclusion criteria [13–15].
Reasons for exclusion of other articles were lack of
reporting of clinical outcomes or composition of study
population with all renal insufficient patients. All included
studies were retrospective and single-centered, and are
summarized in Table 1. Table 2 provides the overall
results of each study, and the quality analysis is displayed
in Table 3. More detailed study evaluations are provided
below.
Arnold et al. [13] conducted a retrospective cohort study
to evaluate the use of imipenem-cilastatin 500 mg every
6 h, meropenem 1000 mg every 8 h, and meropenem
500 mg every 6 h in adult febrile neutropenic patients with
intolerances to or failure on cefepime after at least 3 days
of therapy [13]. Data were collected over a 2-year period
(September 1, 2005 to August 31, 2007), and 127 patients
were identified that met inclusion criteria (Table 1). Of
these patients, 40 received imipenem-cilastatin, 29
received traditional meropenem dosing (1000 mg every
8 h), and 58 received alternative meropenem dosing
(500 mg every 6 h). A total of 76% of all patients received
concurrent vancomycin, and there was a statistically sig-
nificant (p = 0.04) difference in empiric antifungal use
between the imipenem–cilastatin, traditional meropenem,
and alternative meropenem groups (40, 76, and 64%,
respectively).
Results of this study are presented in Table 2. No dif-
ferences were found in the primary outcomes of time to
defervescence, need for additional antibiotics, or time to
addition of first antibiotic. Secondary outcomes were also
not significant with regards to duration of treatment, mor-
tality, and seizure activity; all being similar or the same
between all groups. The authors concluded that the study
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did not provide any evidence that the alternative mer-
openem dosing strategy resulted in any adverse effects, but
safety and efficacy of the regimen could not be confirmed.
Limitations included a small sample size, which may have
resulted in insufficient power to detect differences in
clinical outcomes, a highly specific patient population (use
of cefepime prior to carbapenem), and the use of concur-
rent medications which may have confounded the results.
Despite these limitations, this study did not provide any
signal or hypothesis-generating data that counter the use of
the alternative meropenem dosing strategy in febrile neu-
tropenic patients failing treatment with cefepime.
Patel et al. [14] conducted a retrospective cohort study
to determine if an alternative meropenem dosing strategy
(500 mg every 6 h) results in similar clinical outcomes to
traditional dosing and whether this regimen is associated
with any pharmacoeconomic impact [14]. Patient records
for traditional dosing were obtained between January 1 and
September 30, 2004. Traditional dosing was defined as
1000 mg every 8 or 12 h (if creatinine clearance was
25–49 mL/min). Patient records for alternative dosing were
obtained from October 1, 2004 and September 30, 2005, if
they received 500 mg every 6 or 8 h (if creatinine clear-
ance was 25–49 mL/min). All infectious indications that
required meropenem therapy were included aside from
febrile neutropenia and cystic fibrosis. Other exclusion
criteria are listed in Table 1. A total of 100 patients met the
inclusion criteria for the traditional dosing arm, and 192
patients for the alternative dosing arm. Baseline charac-
teristics were similar between groups, including use of
Table 1 Description of studies assessing meropenem dosing regimens of 1 g q8h and 500 mg q6h
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other concurrent medications and the source of infection.
Intra-abdominal and respiratory infections were most
commonly reported.
Results are given in Table 2. Clinical outcomes of
meropenem-related length of hospital stay, in-hospital
mortality, and duration of therapy did not significantly
differ between the two arms. Overall clinical success
(complete or partial resolution of leukocytosis, tempera-
ture, and clinical signs and symptoms of infection) rates
were also similar, yet the median time to resolution of
infection was shorter in the alternatively dosed patients
(n = 156) versus the traditionally dosed ones (n = 87) (1.5
vs. 3 days, p\ 0.0001, respectively). Pharmacoeconomic
analyses demonstrated a decrease in drug acquisition costs
with the alternative dosing strategy. Specifically, median
cost per patient for the duration of therapy was US$439.05
for traditional dosing and US$234.08 for alternative dosing
(p\ 0.0001). The authors estimated that within the 1 year
Table 2 Results of studies assessing meropenem dosing regimens of 1 g every 8 h and 500 mg every 6 h







Median time to defervescence (days) 3 (n = 44) 2 (n = 22) HR 0.881, 95% CI
0.511–1.519
Need for additional antibiotics 8/58 patients (13.8%) 5/29 patients
(17.2%)
NS
Median (range) time to addition of first antibiotic
(days)
1 (1–6) (n = 58) 2 (1–22) (n = 29) HR 0.645, 95% CI
(0.208–1.998)




In-hospital mortality 11.5% (n = 192) 8% (n = 100) p = 0.238
Median (range) meropenem-related length of
stay (days)
9 (1–67) (n = 192) 7 (1–44) (n = 100) p = 0.141
Median (range) duration of therapy (days) 4 (1–27) (n = 192) 5 (2–22) (n = 100) p = 0.055
Success rate 92.1% (n = 192) 90.9% (n = 100) p = 0.72
Kotapati et al.
[15]
Clinical success rate (evaluable patients) 28/36 (78%) 32/39 (82%) p = 0.862
Clinical success rate (monotherapy) 24/29 (83%) 17/21 (81%) p = 1.000
Microbiological success rate 19/30 (63%) 19/24 (79%) p = 0.334
Rate of response (days to normalization of
temperature)
3 (n = 36) 3 (n = 39) p = 0.476
Rate of response (days to normalization of
lymphocyte count)
4 (n = 36) 4.5 (n = 39) p = 0.927
Meropenem-related length of stay (days) [IQR] 7 [4.8–13] (n = 45) 7.5 [4–10] (n = 40) p = 0.891
CI confidence interval, HR hazard ratio, IQR interquartile range, NS non-significant (p[ 0.05)
Table 3 Quality evaluation of identified studies according to the CASP-UK Cohort Study Checklist [12]
Question Arnold et al. [13] Patel et al. [14] Kotapati et al. [15]
Did the study address a clearly focused issue? Yes Yes Yes
Did the authors use an appropriate method to answer their question? Yes Yes Yes
Was the cohort recruited in an acceptable way? Yes Yes Yes
Was the exposure accurately measured to minimize bias? Yes Yes Yes
Was the outcome accurately measured to minimize bias? Can’t tell Can’t tell Yes
Have the authors identified all important confounding factors? Yes Yes Yes
Was the follow-up of subjects complete enough? Yes Yes Yes
What are the results of this study? Table 2 Table 2 Table 2
How precise are the results? No Can’t tell Can’t tell
Do you believe the results? Can’t tell Can’t tell Can’t tell
Can the results be applied to the local population? No Can’t tell Can’t tell
Do the results of this study fit with other available evidence? Yes Yes Yes
CASP Critical Appraisal Skills Programme
76 K. J. Wilby et al.
of data collection, a saving of approximately US$40,000
occurred for the 192 patients treated. Limitations of the
study include the small sample size and the single-centered
design. In addition, a high percentage of concomitant
antimicrobial therapy was observed in all patients (56%
traditional group vs. 66% alternative group). Despite these
limitations, this study does not report evidence of harm
using the alternative regimen, and the regimen may result
in institutional cost savings.
Kotapati et al. [15] completed a retrospective cohort
study to assess the clinical and economic outcomes asso-
ciated with meropenem 1000 mg every 8 h and 500 mg
every 6 h [15]. Study characteristics are given in Table 1.
Patients were included if they received at least one dose of
meropenem between January and December 2002. Patients
were grouped according to the same traditional and alter-
native dosage groups as per Patel et al. [14], and were
excluded if they previously received antibiotics, except in
the case of antibiotic failure. Patients were included in the
pharmacoeconomic analysis if they received 1 full day of
meropenem and were considered clinically evaluable if
they received at least 3 days. A total of 85 patients (40
traditional dosing and 45 alternative dosing) met the
inclusion criteria for the pharmacoeconomic analysis, and
75 (39 traditional dosing and 36 alternative dosing) were
clinically evaluable. Baseline characteristics were similar
between groups. The most common site of infection was
the lung.
Results are presented in Table 2. No difference in
clinical outcomes was observed among groups. These
included clinical success rate (acute or partial resolution of
acute signs and symptoms of infection at end of mer-
openem therapy or discharge), microbiological success
rate, response rate (days to normalization of temperature or
lymphocyte count), and length of stay. Pharmacoeconomic
analyses favored the alternative dosing regimen. Specifi-
cally, drug acquisition costs per patient were lower in the
alternative dosing group compared with the traditional
dosing group (US$576 vs. US$982, respectively,
p = 0.009). Acquisition costs plus all costs associated with
concomitant antibiotics and treatment of adverse effects
per patient were also significantly reduced in the alternative
dosing group compared with traditional dosing (US$1035
vs. US$1797, respectively, p = 0.008). However, these
costs in addition to meropenem-related length of stay costs
were not significantly different between both groups
(US$19,934 vs. US$16,087, respectively, p = 0.420). The
authors concluded that the two regimens were similar from
a clinical perspective, but the alternative regimen was
advantageous from an economic perspective. Limitations
included the small sample size (i.e., lack of power to detect
differences) and the lack of generalizability of economic
data outside of the study center. Despite these limitations,
this study did not provide any evidence of harm and sug-
gested that drug acquisition costs are likely lower with the
alternative dosing regimen.
4 Discussion
This paper examined the published literature reporting
clinical outcomes associated with two meropenem dosing
strategies. Three comparative studies were identified that
did not demonstrate any significant differences in clinical
outcome between traditional and alternative dosing
[13–15]. It was shown, however, that alternative dosing
may have economic advantages due to lower drug acqui-
sition costs [14]. Despite identified limitations related to
study design, small sample size, and lack of generaliz-
ability, the data presented in this review provide insight
into an important question facing health institutions
worldwide.
The consistent findings among the three studies were
that meropenem 500 mg every 6 h did not appear to have
any differences in clinical outcomes, as compared to the
1 g every 8 h regimen. Although the small sample sizes
likely lacked the power to detect meaningful differences
between groups, the similar efficacy can be theoretically
supported by meropenem’s pharmacokinetic and pharma-
codynamic profile [8]. As a time-dependent kill antibiotic,
the more frequent dosing interval with the alternate dosing
regimen (500 mg every 6 h) would result in the same or
higher percentage of time above the MIC as the traditional
regime (1 g every 8 h) [9]. Of course, any recommenda-
tions to implement alternative dosing must be done cau-
tiously based on the limited evidence, especially for more
severe infections.
A potential advantage of the alternative regimen could
be the cost savings associated with drug acquisition [14].
Costs of meropenem likely differ worldwide, but the
alternative dosing strategy results in a 2-g total daily dose,
as compared to 3 g with traditional dosing. This difference
of 33% may yield cost savings to health systems, especially
in settings with high carbapenem utilization. If clinical
outcomes are indeed deemed similar between dosing
strategies, institutional switches to the alternative dosing
strategy may reduce antimicrobial costs. Any savings,
however, must be weighed against indirect costs such as
increased workload regarding drug preparation by phar-
macy staff and drug administration by nursing staff, and
patient quality of life with the receipt of an extra dose per
day. It should also be noted that the studies reporting
economic outcomes were completed in 2004 and 2007 and
drug acquisition costs have likely changed since this time.
Therefore, any economic advantage must be studied at the
institutional level.
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Findings must be interpreted in light of several limita-
tions. The quality analysis identified a few methodological
flaws, which should be noted. First, only three studies were
identified, and each was limited by the retrospective nature
of the study design. However, it is not likely that a
prospective study would be conducted to address this
particular question, and so this would become the best
evidence available. Second, studies were limited by small
sample sizes, which likely resulted in decreased power to
detect differences between groups. Third, two studies
included a broad range of infectious conditions, and thus it
is not clear if the results obtained are applicable to a
specific population [14, 15]. On the other hand, one study
specifically focused on febrile neutropenia patients who
were intolerant to or failed on cefepime therapy and
therefore lacks generalizability as a whole [13].
Despite the limitations mentioned, conclusions can be
drawn from the data obtained. From a clinical perspective,
there is no evidence to suggest that an alternativemeropenem
dosing strategy of 500 mg every 6 h is inferior to traditional
dosing of 1 g every 8 h. The alternative strategy could
therefore be considered as a potential therapeutic dosing
regimen for patients requiring meropenem. Although strong
evidence is lacking to support widespread changes to dosing
guidelines, it is not likely that well-designed trials will be
completed, because of resource limitations. Therefore, those
already employing this practice should be encouraged to
report long-term outcomes for both efficacy and safety. At
the institution level, these clinical outcomes should be
studied alongside economic outcomes, in order to determine
overall benefits of alternative dosing.
In summary, there are limited data available that support
the alternative dosing regimen of meropenem 500 mg
intravenously every 6 h. Based on a clinical perspective
and on pharmacokinetic/pharmacodynamics principles, this
regimen appears to be safe and efficacious. Future studies
are needed to confirm the findings of this review, especially
in high-risk populations such as immunocompromised
patients or those with severe infections.
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